

1 **SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the**
2 **subsequent incidence of COVID-19 in 100,000 healthcare**
3 **workers: do antibody positive healthcare workers have less**
4 **reinfection than antibody negative healthcare workers?**

5

6 Short Title: The impact of detectable anti-SARS-CoV-2 antibody on the incidence of COVID-
7 19

8

9 **Authors and affiliations**

10 S. Wallace*[§], V. Hall*, A. Charlett, P.D. Kirwan, M.J. Cole, M. Shrotri, S. Rokadiya, B. Oguti,
11 A. Vusirikala, M. Zambon, T. Brooks, M. Ramsay, C.S. Brown, M.A. Chand, S. Hopkins

12 * Joint first author

13 [§]Corresponding Author

14 Affiliation: COVID-19 response, Public Health England, London, UK

15

16 **Abstract**

17 **Background**

18 The overall risk of reinfection in individuals who have previously had COVID-19 is unknown.

19 To determine if prior SARS-CoV-2 infection (as determined by at least one positive
20 commercial antibody test performed in a laboratory) in healthcare workers confers future
21 immunity to reinfection, we are undertaking a large-scale prospective longitudinal cohort
22 study of healthcare staff across the United Kingdom.

23

24 **Methods**

25 Population and Setting: staff members of healthcare organisations working in hospitals in the
26 UK

27 At recruitment, participants will have their serum tested for anti-SARS-CoV-2 at baseline and
28 using these results will be initially allocated to either antibody positive or antibody negative
29 cohorts. Participants will undergo antibody and viral RNA testing at 1-4 weekly intervals
30 throughout the study period, and based on these results may move between cohorts. Any
31 results from testing undertaken for other reasons (e.g. symptoms, contact tracing etc.) or
32 prior to study entry will also be included. Individuals will complete enrolment and fortnightly
33 questionnaires on exposures and symptoms. Follow-up will be for at least 12 months from
34 study entry.

35 Outcome: The primary outcome of interest is a reinfection with SARS -CoV-2 during the
36 study period. Secondary outcomes will include incidence and prevalence (both RNA and
37 antibody) of SARS-CoV-2, viral genomics, viral culture, symptom history and
38 antibody/neutralising antibody titres.

39 **Conclusion**

40 This large study will help us to understand the impact of the presence of antibodies on the
41 risk of reinfection with SARS-CoV-2; the results will have substantial implications in terms of
42 national and international policy, as well as for risk management of contacts of COVID-19
43 cases.

44 **Trial Registration**

45 IRAS ID 284460, HRA and Health and Care Research Wales approval granted 22 May
46 2020.

47 **Key Words**

48 COVID-19, SARS-CoV-2, Antibodies, Reinfection, Healthcare, Staff, Cohort, Protocol

49

50 1. Introduction

51 SARS-CoV-2, a novel coronavirus which causes respiratory illness, was first identified in
52 China in December 2019.(1) Following global spread of the virus, the World Health
53 Organization declared a national pandemic in March 2020. Globally nearly 64 million cases
54 have been reported to the World Health Organization by 4 December 2020, with 1,488,120
55 deaths attributed to COVID-19 (2), and both the virus and the measures put in place to
56 reduce spread have led to significant economic and societal impacts. Whether individuals
57 can be re-infected with SARS-CoV-2 is a crucial question both for contact management of
58 individuals exposed to the virus, but also from the perspective of the implications for the
59 effectiveness of any vaccine produced.

60 The risk of reinfection for individuals who have previously had COVID-19 is unknown. There
61 have been a number of case reports which have identified individuals who have been
62 reinfected with a new and genetically distinct SARS-CoV-2 genome from their original
63 infection.(3-8) One recent study of the antibody prevalence from three large cross-sectional
64 surveys in England, measured using a self-administered test, found that over a three month
65 period population prevalence dropped from 6.0% (5.8, 6.1) to 4.4% (4.3, 4.5), suggesting
66 waning antibodies in the population.(9) Several longitudinal studies have looked at titres over
67 time, with one UK based study showing waning of neutralising antibodies over 3 months but
68 with large differences between individuals (those with more severe disease had higher
69 antibody titres at their peak)(10), while another study in Iceland demonstrated maintenance
70 of IgG titres over 4 months.(11) However the implications of these findings are unclear. We
71 know that other human coronaviruses demonstrate similar patterns of waning titres over
72 time, with individuals able to be reinfected and shed virus.(12)

73 Many hospitals are choosing to screen certain staff groups regularly for SARS-CoV-2 to
74 reduce the risk of transmission to patients and colleagues. Healthcare workers have
75 consistently been found to have higher positive antibody prevalence compared with the

76 general population; published surveys in UK hospital staff have reported prevalences of
77 24.5% in a Birmingham Hospital(13), and 31%(14) and 44%(15) in London. For a study
78 examining the risk of reinfection an ideal population to examine this question is one with a
79 high baseline antibody prevalence, where there is an indication for routine SARS-CoV-2
80 screening, easy access to testing and likely to be higher ongoing exposure to SARS-CoV-2
81 in hospitals.

82 The SIREN (**S**arscov2 Immunity & **RE**infection Evaluation**N**) study aims to answer the key
83 question of whether prior SARS-CoV-2 infection confers future immunity to SARS-CoV-2
84 reinfection. The study design will also enable important secondary outcomes to be
85 examined, including antibody titre change over time, incidence of new infections, clinical and
86 demographic factors correlating with antibody presence, phylogenetic relatedness of
87 healthcare worker infections and ability to culture viable virus from those who are reinfected.

88

89 2. Methods

90 2.1. Study design

91 This is a prospective longitudinal cohort study which will enrol up to 100,000 individuals and
92 follow them up for 12 months with regular data collection. Individuals will be enrolled
93 between June 2020 and March 2021.

94 2.2. Study objectives

95 The overall aim of this study is to determine if prior SARS -CoV-2 infection in health care
96 workers confers future immunity to reinfection.

97

98 **Primary Objective:** To determine whether the presence of antibody to SARS-CoV-2 (anti-
99 SARS-CoV-2) is associated with a reduction in the subsequent risk of reinfection over short
100 term periods (reviewed monthly) and the next year.

101 **Secondary Objectives:**

- 102 1. To estimate the prevalence of SARS-CoV-2 infection in staff working in healthcare
103 organisations by region, using baseline serological testing at study entry and
104 symptom history from January 1st 2020 to date of study entry
- 105 2. To estimate the subsequent incidence of symptomatic and asymptomatic SARS-
106 CoV-2 infection and determine how this varies over time, using regular PCR testing
107 (combined with any intercurrent symptomatic testing)
- 108 3. To estimate cumulative incidence of new infections in staff working in healthcare
109 organisations stratified by age, sex, staff group, ethnicity and co-morbidities
- 110 4. To measure the ability to culture viable virus from cases of reinfection diagnosed by
111 PCR and whether those who are persistently positive on PCR are continuing to shed
112 viable virus

- 113 5. To use genomic comparison to determine whether healthcare workers who become
114 PCR-positive for a second time within a defined time frame are experiencing
115 persistent infection or reinfection
- 116 6. To determine how serological response changes over time
- 117 7. To determine whether there is a relationship between serological response (using
118 enzyme immunoassay detection of IgG) and the presence of neutralising (protective)
119 antibodies
- 120 8. To identify serological, demographic or clinical factors that correlate with the
121 presence of neutralising antibodies, including subsequent disease severity
- 122 9. To investigate the phylogenetic relatedness of SARS-CoV-2 viruses causing staff
123 working in healthcare organisations infections

124

125 2.3. Participants and recruitment

126 **Population**

127 The eligible population are staff members of healthcare organisations. Staff are recruited
128 from healthcare organisations participating as SIREN sites, and all NHS Trusts/Health
129 Boards (organisations that manage hospitals) in England, Scotland, Wales and Northern
130 Ireland have been invited to join. At a later stage, recruitment may be extended to staff from
131 other healthcare organisations such as primary care organisations and the independent
132 sector.

133 **Eligibility**

134 A participants is eligible to join the study if they are a healthcare organisation staff member
135 who works in a clinical setting where patients are present, can provide written consent, and

136 is willing to remain engaged with follow-up for 12-months. Temporary short-term staff
137 members are not eligible.

138 **Recruitment and consent**

139 Sites are responsible for recruiting eligible participants, according to their own processes.

140 Sites are recommended to circulate all staff communications inviting volunteers and to

141 monitor the demographics of their cohort as they recruit, aiming to represent their staff

142 population. There are no requirements for quotas or structured sampling.

143 Interested and eligible potential participants are provided with a unique study number and

144 passcode by their site research team and directed to enrol in the study by completing the

145 online consent form and enrolment questionnaire. On completion of the online consent form

146 and enrolment questionnaire, participants join the SIREN cohort. Site research teams are

147 automatically informed of participant enrolment in real-time, and can then contact

148 participants to arrange testing.

149

150 **2.4. Data collection**

151 **At enrolment**

152 At enrolment participants complete an online questionnaire and submit serum and a nose

153 swab (or nose and throat swab) for SARS-CoV-2 antibody and nucleic acid amplification

154 (NAAT) testing. Participants will have up to 10mls of blood taken by venepuncture at

155 enrolment and follow-up. The questionnaire collects information on participant

156 demographics, work environment, symptom and testing history, participation in clinical trials

157 and known COVID exposures since 1 January 2020.

158 **At follow-up**

159 Participants undergo regular repeat NAAT and antibody testing throughout the study period,
160 initially at fortnightly intervals, although frequency may be revised (weekly to monthly)
161 subject to local/national epidemiology and feedback. Participants are sent a link to an online
162 follow-up questionnaire on a fortnightly basis, with a reminder message sent after 2 days if
163 the follow-up questionnaire is not completed. These questionnaires capture information on
164 symptoms, exposures and subsequent enrolment in vaccine or prophylaxis trials.

165 **Testing at SIREN site laboratories and data sources**

166 For all participants NAAT (typically PCR) and antibody testing is undertaken locally at the
167 laboratory used by their healthcare organisation. The healthcare organisation is responsible
168 for issuing results to the participants as per local procedures. Testing platforms, including
169 choice of antibody assay, is determined locally.

170 All laboratories for SIREN participating sites submit their antibody and antigen testing data
171 into Public Health England's (PHE) Second Generation Surveillance System (SGSS).
172 Testing data from sites on SIREN participants is obtained by the PHE SIREN team through
173 deterministic linkage, based on the NHS number (or equivalent unique identifier for Devolved
174 Administrations) and additional patient identifiers provided by participants in the enrolment
175 questionnaire. Linkage to site testing data for participants in Devolved Administrations is
176 organised with the support of their respective public health agencies. At enrolment,
177 participants consent for the SIREN team to link all their historic and future SARS -CoV-2
178 testing data, including tests undertaken prior to enrolment, and tests taken outside SIREN,
179 such as tests taken due to symptoms or exposures.

180 2.5. Testing at Public Health England

181 **Serology**

182 For all participants, at enrolment an aliquot of 2ml serum will be shipped to and stored in the
183 PHE biobank. At follow-up, serum samples for participants who have ever been antibody
184 positive or antigen positive or have enrolled in a vaccine trial will be sent to and stored at the
185 PHE biobank.

186 At enrolment, all participants will have their serum re-tested by PHE for antibodies to SARS-
187 CoV-2, including the Roche Elecsys Anti-SARS-CoV-2 spike (S) and nucleocapsid (N)
188 protein assays(16) and additional in-house assays to examine for neutralising antibody.
189 Individuals will be classified as seropositive or seronegative based on PHE antibody testing
190 for N and S.

191 In addition to the cohort serological characterisation at enrolment described above,
192 seropositive participants in whom reinfection is identified, plus a cohort of matched non-
193 infected seropositive controls, will have their sera further characterised using additional
194 assays and for the presence of neutralising antibody, to provide hypothesis generating data
195 on mechanisms of protective immunity.

196 **Genomic analysis**

197 All positive samples from participants will be sequenced as part of the routine sequencing of
198 NHS residual samples in COG-UK Consortium laboratories. For participants who have more
199 than one positive PCR test, genomes will be compared where possible to provide evidence
200 to support reinfection or persistent infection. Phylogenetic analysis of SARS -CoV-2 from
201 staff in healthcare organisations, using the study samples and the wider collection of
202 genomes available through the COG-UK Consortium, will also be undertaken as an
203 exploratory analysis into the diversity and spread of SARS -CoV-2 in healthcare workers.

204 **Viral Culture**

205 Participants with possible reinfection or persistent infection will be identified and viral culture
206 requested. This may be on residual sample from the swab already taken, but in certain
207 circumstances (e.g. viral culture not possible on the residual sample) we may request
208 another swab is taken and sample sent for culture.

209 **T-cell assays and other studies**

210 Participants who are persistently NAAT positive, have potentially been reinfected, or have
211 discordant serology may be contacted by the SIREN Study Team to link into optional
212 regional sub-studies e.g. assessing T cell assays and antibody dynamics.

213

214 **2.6. Sample size and power**

215 A simulation approach using a mixed effects Poisson regression model has been used to
216 estimate the power to detect relative differences between the study cohorts. Our key
217 assumptions include that 25% of our cohort will be seropositive at enrolment (based on 20%
218 of staff who were asymptomatic and tested positive in one London hospital between 23
219 March and 2 May 2020(14)), and a total attrition of 35%, (unaffected by serostatus and
220 occurring at a constant rate). The proportion of seropositive recruits at each site has been
221 obtained from a Gaussian distribution with a mean of 0.25 and standard deviation of 0.05 to
222 reflect expected inter-site variation.

223 Power was estimated as the proportion of simulations for which the Wald statistic p value for
224 the estimated incidence rate ratio in the seropositive compared to seronegative cohorts was
225 less than 0.05. Our simulations found that there is statistical power of 80% or greater to
226 detect a relative decrease of 30% or greater in cumulative incidence, provided the
227 cumulative incidence in the seronegative group is in excess of 5%; even taking the
228 cumulative incidence to as low as 2% in the seronegative group there is still sufficient power
229 of in excess 80% for relative decrease of 80% or greater.

230 It was assumed that on average 250 participants would be recruited from each selected
231 healthcare organisation, with a standard deviation of 50. The cumulative incidence in each
232 site in the seronegative cohort has been simulated using Gaussian distributions with means
233 of 0.05, 0.1, 0.2 and 0.3 each with a coefficient of variation of 0.2. This range represents that
234 which is feasible to observe over a 12-month period, given the behavioural and social
235 interventions still being employed during the study to control transmission.

236 A study duration of 52 weeks has been assumed with the inter-test period of 2 weeks.

237 It was assumed that the cumulative incidence in the seronegative cohort was 30% with a
238 between trust coefficient of variation of 0.1, reflecting levels of seropositivity in HCWs at the
239 time. Relative reductions in cumulative incidence in the seropositive cohort was varied
240 between 1 (no protection from infection) to 0.1 (antibody effectiveness of 90%). Units in the
241 simulations were allocated to be infected or not, using a draw from a Bernoulli distribution
242 with p equal to the site and cohort specific simulated cumulative infection rate. A simplifying
243 assumption of a constant infection rate over the study period has been used.

244 For each scenario a set of 200 simulations were performed. For each simulation, the total
245 number of infections and person weeks of follow-up was calculated for each cohort in each
246 organisation. This data was analysed using a mixed effects Poisson model, using the natural
247 logarithm of the person weeks as an offset. These are presented in Table 1, indicating that
248 there is sufficient power for all but the smallest immune efficacy of 0.1 i.e. a 10% reduction in
249 incidence in the seropositive cohort. Such a small reduction is indicative of a level of
250 protection unable to provide a means of controlling the pandemic via natural herd immunity.

251

252 **Table 1: Power estimates obtained via simulation for a range of immune**
253 **effectiveness and cumulative incidence**

Cumulative incidence in the seronegative at baseline cohort (per 100 participants) in 12 months	Immune Effectiveness				
	10%	20%	30%	40%	50%
0.05	0.15	0.44	0.79	0.98	1.00
0.1	0.20	0.77	0.99	1.00	1.00
0.2	0.53	0.99	1.00	1.00	1.00
0.3	0.67	1.00	1.00	1.00	1.00

254

255 **2.7. Statistical Analysis Plan: primary outcome measure**

256 All enrolled participants will be included in analyses, which will account for clustering by
257 research site. Analyses will be conducted at regular intervals following sufficient events of
258 interest.

259 Estimates of both cumulative incidence and incidence density in the seropositive and
260 seronegative cohorts will be obtained using mixed effects models assuming counts of PCR
261 positive have a negative binomial distribution, a log link function, and the natural logarithm of
262 the total number of subjects or the total follow-up time use as an offset, respectively.

263 Inclusion of a binary predictor indicating the serostatus of the cohort into this model will
264 provide estimates of the incidence rate ratio. Sites will be incorporated as a random intercept
265 to account for unmeasured, shared, site level factors. To account for a non-constant force of
266 infection, calendar month will be incorporated as an additional random effect. An
267 assessment of the role of factors such as age, gender and ethnicity in immunity will be
268 explored by inclusion of interactions within the model between each and serological status.

269 While the above analytical approaches provide a “classical” person-years approach to
270 prospective cohort analysis and provide familiar measures of association, it may be
271 inadequate to assessment of immunity provided by seroconversion. As it is expected that
272 seropositivity is likely to confer a degree of short to median term protection for a SARS-CoV-

273 2 infection, multi-state and parametric cure rate models incorporating frailty will also be
274 employed. Bayesian approaches to cure rate models with frailty as describe by deSouza(17)
275 will be employed.

276 It is also possible to introduce “misclassification” of state into the multi state model, providing
277 an estimate of sensitivity to account for imperfect serological tests. Approaches like those
278 proposed by Jackson(18) will be employed.

279 **Procedure for Accounting for Missing, Unused, and Spurious Data**

280 Analyses will be restricted to cases with antibody and PCR tests. The PCR test for virus is
281 being used as a diagnostic test and hence has high performance. Sufficient sera will be
282 obtained to re-run the immunological assays in case of initial assay failure. For similar
283 reasons we do not anticipate that spurious data will be obtained.

284 **Procedures for Reporting any Deviation(s) from the Original Statistical Plan**

285 Deviations from the original statistical plan or the statistical analysis plan will be described
286 and justified in the analysis reports.

287 Data will be analysed using STATA.v15 and R software.

288

289 **3. Study oversight**

290 Oversight is provided by the Study Management Group, chaired by the Chief Investigator,
291 with representatives from Public Health England, Public Health Scotland, Public Health
292 Wales, Public Health Agency (Northern Ireland), and the COVID-19 Genomics Consortium
293 UK (COG-UK).

294 The study follow-up period will end by default 12 months following the enrolment of the last
295 participant, but by consensus of the Study Management Group and funder may be
296 terminated sooner if findings are sufficient. There are no formal stopping rules for futility,

297 utility or lack of power. The final decision to terminate the study will be made by Public
298 Health England and Department for Health and Social Care.

299

300 4. Ethics and Consent

301 The study has received approval from Berkshire Research Ethics Committee and has also
302 received support from NIHR as an urgent public health study, which allows central research
303 network resources to recruit participants. All participants have provided informed consent
304 prior to entry to the study and have the option to withdraw at any time. At withdrawal,
305 participants can choose to have their data or samples retained or destroyed, or partial
306 variations. Protocol deviations and breaches will be recorded by the site research teams and
307 the Sponsor will be informed of any serious breaches within one working day.

308

309 5. Discussion

310 5.1. Strengths

311 This study is the largest national longitudinal study of this scale examining the question of
312 reinfection with SARS -CoV-2 that the authors are aware of globally. In a system where staff
313 members may be tested in different settings depending on the timing and reasons for testing
314 (community testing hubs, other hospitals, primary care), the automated method of data
315 extraction and access to national testing data means that the study is less likely to miss
316 potential cases. As far as possible the study is designed to run alongside normal laboratory
317 processes; laboratories use the same assays and procedures which are in place for all other
318 testing, reducing additional burden on sites.

319 The study design lends itself to forming sub-cohorts for more detailed investigations. It has
320 active research collaborations with immunology researchers from the UK Research and

321 Innovation (UKRI) Immunology consortium to investigate T cell responses and with the
322 Wellcome Trust funded Humoral Immune Correlates of COVID-19 (HICC) consortium to
323 investigate humoral immune responses.

324

325 5.2. Weaknesses

326 Cohort retention will be an important consideration for the study team, to avoid losing power
327 to detect the primary outcome and potential introduction of bias if there is differential attrition
328 by cohort. To mitigate this, the study team will actively monitor withdrawals and participant
329 feedback, to implement improvements and will establish direct participant communications
330 (e.g. a newsletter) to promote engagement. Over the study period, it is likely that vaccine
331 trials and usage will increase; adjustments to the study methodology may be required to
332 permit co-enrolment and retain SIREN participants who subsequently receive vaccines, and
333 to incorporate vaccine efficacy into the analyses. Differences in demographics, general
334 health and ongoing risk of exposure between healthcare workers and the general population
335 mean that the results may not be fully generalisable to the UK population.

336

337 6. Declarations

338 6.1. Ethics

339 The study has received ethical approval from Berkshire Research Ethics Committee
340 (20/SC/0230). Study participants will provide informed written consent prior to study entry.

341 6.2. Competing Interests

342 The authors have no competing interests to declare

343 6.3. Funding

344 The study is funded by the Department of Health and Social Care and Public Health
345 England, with contributions from the Scottish, Welsh and Northern Irish governments.

346 6.4. Authors' contributions

347 SH is the Chief Investigator and conceived the study. SH, CB, and MAC designed the study
348 and drafted the first protocol, with substantial design contribution from MR, MZ and TB. AC
349 wrote the statistics plan and power calculations. VH, SW, MJC, PK, MS, SR, BO and AV
350 were responsible for designing or updating aspects of the study design. SW and VH re-
351 drafted the most recent protocol. SH, SW and VH prepared the manuscript for publication,
352 with the review and approval of the other authors.

353 6.5. Authors' Acknowledgements

354 The authors would like to thank our partners in the Devolved Administrations, particularly
355 Lesley Price and Muhammad Sartaj, for their contribution and advice.

356 6.6. Availability of Data

357 Not applicable

358 6.7. Consent for Publication

359 Not applicable

360

361 7. References

- 362 1. Government of the Hong Kong Special Administrative Region. CHP closely monitors
363 cluster of pneumonia cases on Mainland 31/12/2019 2019 [updated 31/12/2019].
364 Available from: <https://www.info.gov.hk/gia/general/201912/31/P2019123100667.htm>.
- 365 2. World Health Organization. COVID-19 Dashboard 2020 [4/12/2020]. Available from:
366 <https://covid19.who.int/>.
- 367 3. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B,
368 Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct
369 strain. *Clin Infect Dis*. 2020.
- 370 4. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a
371 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome
372 sequencing. *Clin Infect Dis*. 2020.
- 373 5. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Márquez S, Gutierrez B, Rojas-Silva P,
374 et al. A case of SARS-CoV-2 reinfection in Ecuador. *Lancet Infect Dis*. 2020.
- 375 6. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, et al. A Case of
376 Early Re-infection with SARS-CoV-2. *Clin Infect Dis*. 2020.
- 377 7. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic
378 evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis*. 2020.
- 379 8. Gupta V, Bhojar RC, Jain A, Srivastava S, Upadhayay R, Imran M, et al. Asymptomatic
380 reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2.
381 *Clin Infect Dis*. 2020.
- 382 9. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining
383 prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults.
384 *medRxiv*. 2020:2020.10.26.20219725.
- 385 10. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal
386 observation and decline of neutralizing antibody responses in the three months following
387 SARS-CoV-2 infection in humans. *Nat Microbiol*. 2020;5(12):1598-607.

- 388 11. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et
389 al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med*.
390 2020;383(18):1724-34.
- 391 12. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
392 *Immunity*. 2020;53(2):248-63.
- 393 13. Shields A, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, et al. SARS-CoV-2
394 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional
395 study. *Thorax*. 2020;75(12):1089-94.
- 396 14. Grant JJ, Wilmore SMS, McCann NS, Donnelly O, Lai RWL, Kinsella MJ, et al.
397 Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS
398 Trust. *Infect Control Hosp Epidemiol*. 2020:1-3.
- 399 15. Houlihan CF, Vora N, Byrne T, Lewer D, Kelly G, Heaney J, et al. Pandemic peak SARS-
400 CoV-2 infection and seroconversion rates in London frontline health-care workers.
401 *Lancet*. 2020;396(10246):e6-e7.
- 402 16. Public Health England, University of Oxford. Evaluation of sensitivity and specificity of
403 four commercially available SARS-CoV-2 antibody immunoassays. 2020.
- 404 17. de Souza D, Cancho VG, Rodrigues J, Balakrishnan N. Bayesian cure rate models
405 induced by frailty in survival analysis. *Stat Methods Med Res*. 2017;26(5):2011-28.
- 406 18. Jackson CH. Multi-State Models for Panel Data: The msm Package for R. *Journal of*
407 *Statistical Software*. 2011;38(8):1-28.